- Home
- PETS vs CLRB Comparison
PETS vs CLRB Comparison
Compare PETS & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PETS | CLRB |
|---|---|---|
| Founded | 1996 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.6M | 12.9M |
| IPO Year | 2003 | 2008 |
Fundamental Metrics
Financial Performance| Metric | PETS | CLRB |
|---|---|---|
| Price | $2.23 | $2.70 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.20 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 85.0K | 46.4K |
| Earning Date | 02-05-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.92 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $273,800,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.98 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.57 | $0.23 |
| 52 Week High | $4.32 | $10.19 |
Technical Indicators
Market Signals| Indicator | PETS | CLRB |
|---|---|---|
| Relative Strength Index (RSI) | 27.56 | 37.29 |
| Support Level | N/A | $2.62 |
| Resistance Level | $3.27 | $3.56 |
| Average True Range (ATR) | 0.12 | 0.24 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 2.08 | 0.00 |
Price Performance
Historical ComparisonAbout PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.